- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Chemical Biology
- ACRF Stem Cells and Cancer
- Bioinformatics
- Cancer and Haematology
- Cell Signalling and Cell Death
- Development and Cancer
- Immunology
- Infection and Immunity
- Inflammation
- Molecular Genetics of Cancer
- Molecular Immunology
- Molecular Medicine
- Population Health and Immunity
- Structural Biology
- Systems Biology and Personalised Medicine
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- Opportunities in platform technologies
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Fut8 Sugar coating immuno oncology
- Intercepting inflammation with RIPK2 inhibitors
- Novel checkpoints NK cells emerge as key players in IO
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting plasmacytoid dendritic cells for systemic lupus erythematosus
- Treating Epstein-Barr virus associated malignancies
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Research fields
- Bioinformatics
- Cancer biology
- Cell death
- Cell signalling
- Clinical translation
- Computational biology
- Drug discovery
- Epigenetics
- Flow cytometry
- Genomics
- Haematology
- Imaging
- Immunology
- Infection
- Inflammation
- Medicinal chemistry
- Personalised medicine
- Proteomics
- Stem cells
- Structural biology
- Systems biology
- Vaccine development
- People
- Anne-Laure Puaux
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Anne Voss
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Edwin Hawkins
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marnie Blewitt
- Associate Professor Matthew Ritchie
- Associate Professor Mike Lawrence
- Associate Professor Nicholas Huntington
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bob Anderson
- Dr Brad Sleebs
- Dr David Komander
- Dr Diana Hansen
- Dr Drew Berry
- Dr Emma Josefsson
- Dr Ethan Goddard-Borger
- Dr Gary Pitt
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Hélène Jousset Sabroux
- Dr Ian Majewski
- Dr Ian Street
- Dr Jacqui Gulbis
- Dr James Vince
- Dr Jason Tye-Din
- Dr Joanna Groom
- Dr John Wentworth
- Dr Julie Mercer
- Dr Kate Sutherland
- Dr Kelly Rogers
- Dr Ken Pang
- Dr Leanne Robinson
- Dr Leigh Coultas
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Marie-Liesse Asselin-Labat
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Melissa Davis
- Dr Michael Low
- Dr Misty Jenkins
- Dr Peter Czabotar
- Dr Philippe Bouillet
- Dr Priscilla Auyeung
- Dr Rhys Allan
- Dr Ruth Kluck
- Dr Samar Ojaimi
- Dr Samir Taoudi
- Dr Sant-Rayn Pasricha
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Stan Balbata
- Mr Steve Droste
- Ms Carolyn MacDonald
- Ms Samantha Ludolf
- Ms Wendy Hertan
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Clare Scott
- Professor David Huang
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Li Wu
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Melanie Bahlo
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- 3D and 4D imaging of thymic T cell differentiation
- Activating https://www.wehi.edu.au/node/add/individual-student-research-page#Parkin to treat Parkinson’s disease
- Activation, regulation, and biological roles of E3 ubiquitin ligases
- Bioinformatics methods for detecting and making sense of somatic genomic rearrangements
- Characterising regulatory T cells in coeliac disease
- Computational melanoma genomics
- Deep profiling of blood cancers during targeted therapy
- Defining the role of necroptosis in platelet production and function
- Determining the migration signals leading to protective immune responses
- Developing mucolytics to treat chronic respiratory diseases
- Developing new tools to visualise necroptotic cell death
- Development of live-cell, automated microscopy techniques for studying malaria
- Development of tools to inform malaria vaccine design
- Discovering new genetic causes of primary antibody deficiencies
- Discovery of novel drug combinations for the treatment of bowel cancer
- Dissecting the induction and integration of T cell migration cues
- Drug targets and compounds that block growth of malaria parasites
- Effects of nutrition on immunity and infection in Asia and Africa
- Eosinophil and neutrophil heterogeneity
- Eosinophil maturation
- Epigenetic regulation of systemic iron homeostasis
- Functional differences between young and old platelets
- Generation of cytokine antagonists
- Genetic dissection of mechanisms of Plasmodium invasion
- Genomic characterisation of epigenetic regulators involved in X inactivation
- High resolution 3-dimensional imaging to characterise metastatic cancers
- High-resolution imaging of host cell invasion by the malaria parasite
- Home renovations: understanding how Toxoplasma redecorates its host cell
- How the epigenetic regulator SMCHD1 works and how to target it to treat disease
- Human monoclonal antibodies against malaria infection
- Identification of malaria parasite entry receptors
- Identification of new therapeutic opportunities for pancreatic cancer
- Identifying disease-causing haplotypes with hidden Markov models
- Interleukin-11 in gastrointestinal bacterial infections
- Investigating mechanisms of cell death and survival using zebrafish
- Investigating new paths to selective modulation of potassium channels
- Let me in! How Toxoplasma invades human cells
- Long-read sequencing for transcriptome and epigenome analysis
- Macro-evolution in cancer
- Mapping DNA repair networks in cancer
- Mapping how multiple malaria episodes are related
- Modelling gene regulatory systems
- Modulation of immune responses by immunosuppressive chemokines
- Molecular basis for inherited Parkinson’s disease mechanism of PINK1
- Mucus at the molecular level
- Novel cell death and inflammatory modulators in lupus
- Plasmodium vivax host-parasite interactions: impact on immunity
- Predicting drug response in cancer
- Programming T cells to defend against infections
- Reconstructing the immune response: from molecules to cells to systems
- Regulation of cytokine signalling
- Screening for regulators of jumping genes
- Target identification of potent antimalarial agents
- Targeting the immune system in cancer
- The role of interleukin-11 in acute myeloid leukaemia
- Transmembrane control of type I cytokine receptor activation
- Uncovering the roles of long non-coding RNAs in human bowel cancer
- Understanding retinal eye diseases with retinal transcriptomic data analysis
- Understanding the role of stromal cells in pancreatic cancer growth
- Unravelling the tumour suppressor network in models of lung cancer
- Utilising pre-clinical models to discover novel therapies for tuberculosis
- Zombieland: evolution of a dead enzyme that kills cells by necroptosis
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Casey Ah-Cann
- Catia Pierotti
- Charlotte Slade
- Daniel Cameron
- Emma Nolan
- Jason Brouwer
- Joy Liu
- Lucille Rankin
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Sarah Garner
- Simona Seizova
- Michael Low
- Sofonias Tessema
- Santini Subramaniam
- Miles Horton
- Alexandra Gurzau
- Tamara Marcus
- Nicholas Chandler
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Brain cancer

Brain cancer causes more deaths in people under the age of 40 than any other cancer, and more deaths in Australian children than any other disease.
Brain cancer survival rates are low and have barely changed in 30 years. Our research into brain cancer is focused on finding new therapies to improve outcomes for the 1600 Australians diagnosed with brain cancer each year.
Brain cancer research at the Institute
Our researchers are:
- Defining the changes in brain cells that allow cancer to grow.
- Working to develop potential new treatments for brain cancer.
- Testing whether drugs that block cell survival could be effective in treating brain cancers.
- Investigating whether the body’s own immune system could be employed to fight brain cancer.
What is brain cancer?
Brain cancer is the abnormal, uncontrolled growth of cells in the brain.
The brain has many different ‘control centres’ that regulate all of our body functions, from breathing to walking. When the cancer grows it can damage these control centres. Even slow growing (benign) tumours can be serious if they affect a vital area of the brain.
The brain is composed of nerve cells that send messages to and from the body, and supporting cells that enable nerve cells to function. Cancer can originate in many different cell types, giving rise to various forms of brain cancer.
Research at the Institute focusses on:
- Glioblastoma multiforme (GBM), the most common and dangerous form of brain cancer. GBM arises from glial cells that support nerve cell function. Less than five per cent of people with GBM survive for five years or longer.
- Diffuse Intrinsic Pontine Glioma (DIPG), the most aggressive form of brain cancer in children. DIPG arises in the brainstem, a critical part of the brain that controls vital functions like breathing.
- Medulloblastomas, which arise in the lower back part of the brain and are the most common brain cancer in children.
Brain cancer rarely spreads (metastasises) to other parts of the body, but cancer cells from other organs can spread to the brain.
Symptoms of brain cancer
The symptoms of brain cancer depend on the type of brain cancer, its size and where it is located in the brain.
Common symptoms of brain cancer include headaches, seizures, nausea and vomiting. Depending on the part of the brain affected, people with brain cancer may also experience changes in speech, vision, hearing, balance, memory, mood, muscle tone or sensation.
Risk factors for developing brain cancer
Most cases of brain cancer arise spontaneously and no cause can be identified. Some factors are known to increase a person’s risk of developing brain cancer, including:
- Ageing
- Exposure to medical radiation, such as radiotherapy, CT scans or x-rays to the head during treatment for a previous cancer
- Having close relatives with brain cancer
How is brain cancer treated?
Treatment for brain cancer is challenging because it affects the body’s most vital organ.
Some brain cancers can be safely removed by surgery, however in other cases this cannot be done without damage to normal brain tissue. For example, DIPG cannot be surgically removed because it originates in the brainstem.
Alongside surgery, standard treatments for brain cancer include radiotherapy and chemotherapy to kill rapidly dividing cells. These therapies have significant side effects and are not always effective at killing brain cancer cells. Side effects are a particular concern for children as their brain is still developing.
Institute scientists are involved in finding new therapies for brain cancer that will improve quality of life and survival for people with this disease.
Brain cancer immunotherapy
Our researchers are investigating whether immune cells could be harnessed to fight brain cancer, an approach called ‘immunotherapy’.
Immunotherapy has led to significant advances in treating cancers such as melanoma and lung cancer. Our researchers are now investigating whether immunotherapy could be used to treat childhood DIPG and adult GBM.
Support for people with brain cancer
Institute researchers are not able to provide specific medical advice to individuals. If you have brain cancer or are supporting somebody with this disease, please visit Cure Brain Cancer or the Brain Foundation or consult your medical specialist.
Researchers:
Super Content:
Funding from Carrie Bickmore’s Beanies 4 Brain Cancer Foundation is helping to advance immunotherapy treatments
Collaborative research has led to a new compound that blocks a protein linked to poor responses to treatment in cancer patients
Dr Ruth Mitchell's research into better treatments for brain cancer has been boosted by a grant from the Brain Foundation.
Our researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells.